» Articles » PMID: 31582259

Current Concepts of Non-coding RNA Regulation of Immune Checkpoints in Cancer

Overview
Journal Mol Aspects Med
Date 2019 Oct 5
PMID 31582259
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

The discovery of immune checkpoint molecules as important regulators of immune responses in healthy individuals as well as immune escape of malignant tumours has led to profound changes in understanding, research and treatment of human cancer. Especially the introduction of immune checkpoint inhibitors in cancer therapy has set anti-cancer therapy on a novel level. With increasing experience of approved CTLA-4 and PD1/PD-L1 inhibitors and the evolution of novel immune checkpoint molecules from pre-clinical models to clinical trials, mechanisms of the regulation of these immune system guiding factors, are of paramount importance to overcome mechanisms of resistance. Non-protein coding RNAs (i.e. non-coding RNAs) such as short microRNAs and long non-coding RNAs are involved in regulating of various cellular processes and have attracted attention of cancer researchers and immunologists over the last years. In the present review, interactions between non coding RNAs and immune checkpoint molecules, within the framework of human cancer, will be discussed and current and developing concepts between the immunological and non-coding RNA world, will be elucidated.

Citing Articles

Plasma long non-coding RNAs as biomarkers for bone marrow infiltration and stage in diffuse large B-cell lymphoma.

Abdelhafiz A, Nabil R, Ghareeb M, Ibraheem D, Ali A, Elshazly S Int J Immunopathol Pharmacol. 2024; 38:3946320241292665.

PMID: 39393794 PMC: 11483759. DOI: 10.1177/03946320241292665.


ImmRNA: a database of RNAs associated with tumor immunity.

Shen F, Li Z, Wu P, Wang J Database (Oxford). 2024; 2024.

PMID: 38970503 PMC: 11227110. DOI: 10.1093/database/baae052.


Non-coding RNAs and exosomal non-coding RNAs in lung cancer: insights into their functions.

Lv X, Yang L, Xie Y, Momeni M Front Cell Dev Biol. 2024; 12:1397788.

PMID: 38859962 PMC: 11163066. DOI: 10.3389/fcell.2024.1397788.


Predictive Biomarkers of Immune Checkpoint Inhibitor-Based Mono- and Combination Therapies for Hepatocellular Carcinoma.

Jeng L, Wang J, Teng C J Cancer. 2024; 15(2):484-493.

PMID: 38169551 PMC: 10758026. DOI: 10.7150/jca.90128.


Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma.

Gautam S, Batra S, Jain M Mol Cancer. 2023; 22(1):118.

PMID: 37488598 PMC: 10367391. DOI: 10.1186/s12943-023-01813-y.